Q-omics provides the consensus-scored IDI1P3 profile across patient tissues and cancer cell-line models. IDI1P3 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IDI1P3 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, IDI1P3 RNA expression shows 9,951 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where IDI1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDI1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDI1P3 survival associations across molecular data types. IDI1P3 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDI1P3 RNA expression–survival associations across cancer types. High IDI1P3 expression shows unfavorable associations in BLCA, CESC, READ, LUAD, SKCM and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for IDI1P3 RNA expression.
This table summarizes IDI1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IDI1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDI1P3 shows higher tumor expression in KIRC. The KIRC box plot shows higher IDI1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .013).
This table shows molecular features associated with IDI1P3 in patient tissues and cancer cell lines. In patient samples, IDI1P3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
